ARS Pharmaceuticals, Inc. (SPRY) Ownership
SPRY ownership summary
as of October 17, 2026- Institutions
- 92.1% of shares outstanding
- Insiders
- 16.18% of shares outstanding
- Shares outstanding
- 99.4M
- Float
- 48.0M shares available to trade
- Short interest
- 30.72% 21.2M shares short
- Days to cover
- 14.70 short interest down 8.2% vs prior month
- Institutions 92.12%
- Insiders 16.18%
SPRY top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | RA Capital Management, LLC | 10.92% | 10.9M | $43.7M | — | June 30, 2026 |
| 2 | Rubric Capital Management LP | 8.59% | 8.5M | $34.3M | +540,861 (+6.8%) | June 30, 2026 |
| 3 | Orbimed Advisors LLC | 8.33% | 8.3M | $33.3M | — | June 30, 2026 |
| 4 | Deerfield Management Co | 7.55% | 7.5M | $30.2M | — | June 30, 2026 |
| 5 | BlackRock Inc | 5.34% | 5.3M | $21.4M | +299,065 (+6.0%) | June 30, 2026 |
| 6 | Tyro Capital Management LLC | 4.48% | 4.5M | $17.9M | +1.5M (+50.2%) | June 30, 2026 |
| 7 | Aberdeen Group PLC | 4.19% | 4.2M | $16.8M | +57,012 (+1.4%) | June 30, 2026 |
| 8 | SR ONE CAPITAL MANAGEMENT, LP | 4.04% | 4.0M | $16.1M | — | June 30, 2026 |
| 9 | State Street Corp | 3.75% | 3.7M | $15.0M | +85,657 (+2.4%) | June 30, 2026 |
| 10 | Capital World Investors | 2.77% | 2.8M | $11.1M | +2.8M (0.0%) | June 30, 2026 |
| 11 | Vanguard Capital Management, LLC | 2.57% | 2.6M | $10.3M | +11,024 (+0.4%) | June 30, 2026 |
| 12 | Millennium Management LLC | 2.41% | 2.4M | $9.7M | −3.6M (−59.9%) | June 30, 2026 |
| 13 | Janney Montgomery Scott LLC | 2.08% | 2.1M | $8.3M | +48,034 (+2.4%) | June 30, 2026 |
| 14 | UBS Group AG | 1.95% | 1.9M | $7.8M | −320,671 (−14.2%) | June 30, 2026 |
| 15 | Geode Capital Management, LLC | 1.71% | 1.7M | $6.8M | +172,193 (+11.3%) | June 30, 2026 |
| 16 | BOOTHBAY FUND MANAGEMENT, LLC | 1.61% | 1.6M | $6.4M | +1.4M (+539.1%) | June 30, 2026 |
| 17 | General American Investors Co Inc | 1.14% | 1.1M | $4.6M | +405,892 (+55.8%) | June 30, 2026 |
| 18 | Third Point, LLC | 1.01% | 1.0M | $4.0M | — | June 30, 2026 |
| 19 | Peregrine Capital Management,LLC | 0.68% | 672K | $2.7M | +672,139 (0.0%) | June 30, 2026 |
| 20 | Tejara Capital Ltd | 0.61% | 607K | $2.4M | +396,639 (+188.5%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 8.3M shares and 2 cut 3.9M.
SPRY top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | American Funds SMALLCAP World A | 2.70% | 2.7M | $10.8M | +2.7M (0.0%) | June 30, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 2.20% | 2.2M | $8.8M | −41,850 (−1.9%) | September 30, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 1.76% | 1.7M | $7.0M | — | August 31, 2026 |
| 4 | iShares Russell 2000 ETF | 1.63% | 1.6M | $6.5M | −18,624 (−1.1%) | September 30, 2026 |
| 5 | abrdn Healthcare Opportunities | 1.11% | 1.1M | $4.5M | −192,176 (−14.8%) | August 31, 2026 |
| 6 | Fidelity Small Cap Index | 0.67% | 670K | $2.7M | +2,843 (+0.4%) | July 31, 2026 |
| 7 | iShares Russell 2000 Growth ETF | 0.59% | 584K | $2.3M | −739 (−0.1%) | September 30, 2026 |
| 8 | iShares Biotechnology ETF | 0.49% | 488K | $2.0M | −3,696 (−0.8%) | September 30, 2026 |
| 9 | UBS (Lux) EF Biotech (USD) P-acc | 0.41% | 410K | $1.6M | −14,506 (−3.4%) | June 30, 2026 |
| 10 | Fidelity Global Healthcare A-Dis-EUR | 0.41% | 408K | $1.6M | +2,357 (+0.6%) | August 31, 2026 |
| 11 | Vanguard Russell 2000 ETF | 0.36% | 354K | $1.4M | +8,697 (+2.5%) | August 31, 2026 |
| 12 | Fidelity Extended Market Index | 0.34% | 340K | $1.4M | +15,735 (+4.9%) | August 31, 2026 |
| 13 | Schwab US Small-Cap ETF™ | 0.34% | 337K | $1.4M | +225 (+0.1%) | September 30, 2026 |
| 14 | Fidelity Select Biotechnology | 0.34% | 335K | $1.3M | — | August 31, 2026 |
| 15 | Empire Life American Value Cl A | 0.32% | 315K | $1.3M | — | June 30, 2026 |
| 16 | A4Investments SICAV SIF ACCI IlanaA2EURH | 0.17% | 170K | $683,400 | +10,000 (+6.2%) | September 30, 2026 |
| 17 | Schwab Small Cap Index | 0.15% | 150K | $602,248 | — | August 31, 2026 |
| 18 | Vanguard Health Care ETF | 0.14% | 144K | $578,301 | +624 (+0.4%) | August 31, 2026 |
| 19 | Stt Strt SPDR® Russell2000 US SmCapETF | 0.13% | 126K | $507,577 | +6,048 (+5.0%) | August 31, 2026 |
| 20 | Fidelity Total Market Index | 0.13% | 125K | $500,755 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
SPRY insider transactions
latest 12| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-13 | Brian Dorsey | Sell | $8.71 | 21,828 | $190,122 |
| 2025-11-12 | Justin Chakma | Sell | $8.87 | 166,380 | $1.5M |
| 2025-08-21 | Kathleen D Scott | Sell | $15.00 | 12,500 | $187,500 |
| 2025-08-21 | Richard E Lowenthal | Sell | $14.49 | 50,000 | $724,500 |
| 2025-08-20 | Sarina Tanimoto | Sell | $14.09 | 37,656 | $530,573 |
| 2025-08-19 | Sarina Tanimoto | Sell | $14.03 | 12,344 | $173,186 |
| 2025-07-01 | Eric Karas | Sell | $16.99 | 15,000 | $254,850 |
| 2025-06-27 | James E Flynn | Sell | $18.46 | 740,149 | $13.7M |
| 2025-06-18 | Eric Karas | Sell | $16.00 | 15,000 | $240,000 |
| 2025-05-20 | Alexander A Fitzpatrick | Sell | $14.10 | 102,969 | $1.5M |
| 2025-05-20 | Brent L. Saunders | Sell | $14.25 | 120,000 | $1.7M |
| 2025-05-20 | Kathleen D Scott | Sell | $14.10 | 50,000 | $705,000 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
SPRY shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns SPRY
Institutional investors own 92.1% of ARS Pharmaceuticals's shares and insiders 16.18%. The largest holder is RA Capital Management, LLC with 10.92% of the shares (10.9M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 2 reduced their stake in the latest filings. Short interest is 30.72% of the float, or 14.70 days of average trading volume. The share count rose 198.1% since 2019.
Related: SPRY analyst forecast, SPRY key metrics. See the SPRY stock overview for the latest quote and news.
SPRY ownership FAQ
Who owns the most ARS Pharmaceuticals stock?
The largest shareholders of ARS Pharmaceuticals are RA Capital Management, LLC (10.92%), Rubric Capital Management LP (8.59%), Orbimed Advisors LLC (8.33%), Deerfield Management Co (7.55%), BlackRock Inc (5.34%).
What percentage of ARS Pharmaceuticals is owned by institutions?
Institutions hold 92.1% of ARS Pharmaceuticals's shares outstanding; insiders hold 16.18%.
Which funds own ARS Pharmaceuticals?
The largest fund holders of ARS Pharmaceuticals are American Funds SMALLCAP World A (2.70%), State Street® SPDR® S&P® Biotech ETF (2.20%), Vanguard MStar Total Stk Mkt Idx Invest (1.76%), iShares Russell 2000 ETF (1.63%), abrdn Healthcare Opportunities (1.11%).
What is ARS Pharmaceuticals's short interest?
21.2M shares of ARS Pharmaceuticals were sold short, 30.72% of the float; at the average daily volume it would take 14.70 days to cover.
Are insiders buying or selling ARS Pharmaceuticals?
Of the latest 12 reported insider transactions in ARS Pharmaceuticals (since May 20, 2025), 0 were purchases and 12 were sales.
How many shares of ARS Pharmaceuticals are outstanding?
ARS Pharmaceuticals has 99.4M shares outstanding, of which 48.0M are in the public float.